JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 50.82 Billion KRW | 18.06% |
| 2022 | 43.72 Billion KRW | 4.55% |
| 2021 | 37.56 Billion KRW | -19.23% |
| 2020 | 37.56 Billion KRW | 11.15% |
| 2019 | 41.65 Billion KRW | 19.45% |
| 2018 | 34.64 Billion KRW | 0.21% |
| 2017 | 34.94 Billion KRW | 0.08% |
| 2016 | 34.77 Billion KRW | 11.91% |
| 2015 | 31.27 Billion KRW | 10.51% |
| 2014 | 26.61 Billion KRW | 38.51% |
| 2013 | 19.45 Billion KRW | 1.05% |
| 2012 | 20.31 Billion KRW | -3.75% |
| 2011 | 20.71 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 12.29 Billion KRW | -1.75% |
| 2024 Q1 | 12.51 Billion KRW | 5.14% |
| 2023 Q2 | 13.11 Billion KRW | -3.15% |
| 2023 Q3 | 10.14 Billion KRW | -22.64% |
| 2023 Q4 | 11.9 Billion KRW | 17.29% |
| 2023 FY | - KRW | 18.06% |
| 2023 Q1 | 13.54 Billion KRW | -5.04% |
| 2022 Q4 | 14.26 Billion KRW | 187.06% |
| 2022 Q1 | 9.94 Billion KRW | 23.58% |
| 2022 Q2 | 10.1 Billion KRW | 1.65% |
| 2022 Q3 | 4.96 Billion KRW | -50.84% |
| 2022 FY | - KRW | 4.55% |
| 2021 Q2 | 9.93 Billion KRW | -8.7% |
| 2021 FY | - KRW | -19.23% |
| 2021 Q4 | 8.04 Billion KRW | -7.6% |
| 2021 Q1 | 10.88 Billion KRW | 37.98% |
| 2021 Q3 | 8.7 Billion KRW | -12.37% |
| 2020 Q3 | 12.76 Billion KRW | -5.8% |
| 2020 FY | - KRW | 11.15% |
| 2020 Q4 | 7.88 Billion KRW | -38.22% |
| 2020 Q1 | 12.25 Billion KRW | 18.45% |
| 2020 Q2 | 13.55 Billion KRW | 10.58% |
| 2019 Q3 | 10.14 Billion KRW | -3.86% |
| 2019 FY | - KRW | 19.45% |
| 2019 Q4 | 10.34 Billion KRW | 1.99% |
| 2019 Q2 | 10.55 Billion KRW | -2.35% |
| 2019 Q1 | 10.8 Billion KRW | 19.55% |
| 2018 Q4 | 9.03 Billion KRW | -9.27% |
| 2018 Q3 | 9.96 Billion KRW | 15.25% |
| 2018 Q1 | 7.02 Billion KRW | -6.11% |
| 2018 FY | - KRW | 0.21% |
| 2018 Q2 | 8.64 Billion KRW | 23.04% |
| 2017 Q4 | 7.48 Billion KRW | -18.43% |
| 2017 Q3 | 9.17 Billion KRW | 2.18% |
| 2017 FY | - KRW | 0.08% |
| 2017 Q2 | 8.97 Billion KRW | -3.85% |
| 2017 Q1 | 9.33 Billion KRW | 30.84% |
| 2016 Q2 | 8.82 Billion KRW | -9.47% |
| 2016 Q4 | 7.13 Billion KRW | -22.61% |
| 2016 Q3 | 9.22 Billion KRW | 4.47% |
| 2016 FY | - KRW | 11.91% |
| 2016 Q1 | 9.74 Billion KRW | 28.1% |
| 2015 Q4 | 7.61 Billion KRW | 3.16% |
| 2015 Q3 | 7.37 Billion KRW | 30.97% |
| 2015 FY | - KRW | 10.51% |
| 2015 Q2 | 5.63 Billion KRW | 0.0% |
| 2014 FY | - KRW | 38.51% |
| 2013 FY | - KRW | 1.05% |
| 2012 FY | - KRW | -3.75% |
| 2011 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -946.226% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 64.044% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 179.376% |
| HANDOK Inc. | 35.06 Billion KRW | -44.95% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 5003.568% |
| Yuhan Corporation | 127.43 Billion KRW | 60.113% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -35.468% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 334.37% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 84.28% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -918.555% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -236.211% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -1385.809% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1022.949% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -43.236% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -946.226% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 375.171% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -675.43% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 203.119% |
| JW Holdings Corporation | 187.88 Billion KRW | 72.947% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 199.22% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 82.079% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 43.03% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 237.128% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -284.79% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -329.741% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -172.472% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -946.226% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 7.538% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 69.178% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 43.03% |
| Yuhan Corporation | 127.43 Billion KRW | 60.113% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -51.838% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -564.448% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 34.012% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 43.03% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -38.747% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 28.187% |
| CKD Bio Corp. | -1.63 Billion KRW | 3217.506% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -2.081% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -56.102% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -38.084% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 237.128% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 18.392% |
| Boryung Corporation | 114.28 Billion KRW | 55.525% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 266.281% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -236.211% |